期刊文献+

233例乳腺癌的治疗及预后分析 被引量:2

原文传递
导出
摘要 目的探讨影响乳腺癌疗效和预后的各种因素。方法回顾性分析233例乳腺癌患者的临床资料,观察生存率,并进行单因素及多因素回归分析。结果全组病例1,2,3,5,8年生存率分别为95.71%、82.83%、61.37%、37.34%、6.90%。单因素分析显示腋窝淋巴结转移数、原发肿瘤大小与生存成负相关(P<0.001);TNM晚期及复发患者中位生存时间明显缩短(P<0.0001);术后辅助化疗方案、病理类型、综合治疗方式与生存相关具有统计学意义。COX比例风险模型分析显示治疗方式、术后辅助性化疗方案和复发具有独立预后意义(P<0.05)。结论乳腺癌患者的远期生存及复发与原发肿瘤大小、腋窝淋巴结转移状态、病理类型、术后辅助性化疗方案及个体化综合治疗方式密切相关。
出处 《中国医师进修杂志》 2006年第6期54-55,63,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献5

  • 1Jatoi I,Hilsenbeck SG,Clark GM,et al.Significance of axillary lymph node metastasis in primary breast cancer.J Clin Oncol,1999,17(8):2334-2340.
  • 2Weir L,Speers C,D'yachkova Y,et al.Prognostic significance of the number of axillary lymph nodes removed in patients with node negative breast cancer.J Clin Oncol,2002,20(7):1793 -1799.
  • 3Simpson JF,Gray R,Dressler LG,et al.Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer:results from the Eastern Cooperative Oncology Group Companion Study,EST 4189.J Clin Oncol,2000,18 (10):2059 -2069.
  • 4Colleoni M,Zahrieh D,Gelber RD,et al.Site of primary tumor has a prognostic role in operable breast cancer:the international breast cancer study group experience.J Clin Oncol,2005,23 (7):1390 -1400.
  • 5廖宁,王坤,吴一龙.NCCN乳腺癌临床指引(2003.2版)[J].循证医学,2003,3(3):167-192. 被引量:8

二级参考文献119

  • 1[99]Wahl R L. Current status of PET in breast cancer imaging,staging, and therapy. Semin Roentgenol,2001,36:250-260
  • 2[100]Conte P F, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate:Results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group [J].J Clin 0nco1,1996,14:2552-2559
  • 3[101]Hortobagyi G N, Theriault R L, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group[J]. J Clin Oncol, 1998,16:2038-2044
  • 4[102]Theriault R L, Lipton A, Hortobagyi G N, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group [J]. J Clin Oncol, 1999,17:846-854
  • 5[103]Berenson J R, Rosen L S, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [J]. Cancer,2001,91:1191-200
  • 6[104]Ali S M, Esteva F J, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients [J]. J Clin Oncol,2001,19:3434-3437
  • 7[105]Hillner B E, Ingle J N, Berenson J R, et al. American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer [J]. J Clin Oncol,2000,18:1378-1391
  • 8[106]Buzdar A, Douma J, Davidson lN, et al. Phase Ⅲ, multicenter,double-blind, randomized study of letrozole, and aromatase inhibitor, for advanced breast cancer versus megestrol acetate[J]. J Clin Oncol,2001,19:3357-3366
  • 9[107]Buzdar A U, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase Ⅲ trials.Arimidex Study Group [ J ]. Cancer, 1998,83:1142-1152
  • 10[108]Bonneterre J, Thurlimann B, Robertson J F, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study [J].J Clin Oncol,2000,18:3748-3757

共引文献7

同被引文献40

  • 1李宇杰,车向明,甘建新,CHAUDHARY Prakash,廖新华,张丹杰,毕铁强.同时性结直肠癌肝转移同期与分期手术疗效的Meta分析[J].西安交通大学学报(医学版),2012,33(3):365-369. 被引量:20
  • 2何义富,王风华,李宇红,林旭滨,姜文奇.拉米夫定在预防乙型肝炎携带的淋巴瘤患者化疗后肝炎发生中作用[J].临床肝胆病杂志,2006,22(6):445-447. 被引量:5
  • 3陈钰,谢青,沈志祥.恶性淋巴瘤治疗相关性乙型肝炎病毒再激活[J].内科理论与实践,2007,2(1):8-12. 被引量:13
  • 4Seals DF, Courtneidge SA. The ADAMs family of metallopmteases : multidomain proteins with multiple functions. Genes Dev,2003,17 (1):7-30.
  • 5Choi JS, Kin KH, Jeon YK, et al. Promoter hypennethylation of the ADAM23 gene in coloreetal cancer cell lines and cancer tissues. Int J Cancer, 2009,124(6) : 1258-1262.
  • 6Takada H,Imoto I,Tsuda H,et al. ADAM23,a possible tumor suppressor gene,is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene, 2005,24(54 ) : 8051-8060.
  • 7Costa FF, Verbisck NV, Salin AC, et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors.Oncogene, 2004,23 ( 7 ) : 1481 - 1488.
  • 8Calmon MF,Colonabo J,Carvalho F,et al. Methylation profile ot genes CDKN2A (p14 and pl6),DAPK1 ,CDHI ,and ADAM23 in head and neck cancer. Cancer Genet Cytogenet, 2007,173 ( 1 ) :31- 37.
  • 9Hagihara A, Miyamoto K, Furuta J,et al. Identification of 27 5'- CpG islands aberrantly methylated and 13 genes silenced in humar pancreatic cancers. Oncogene, 2004,23 ( 53 ) : 8705-8710.
  • 10LeGolvan MP, Resnick M. Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors. J Surg Oncol, 2010,102(8):898-908.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部